ICER Releases Draft Report on NASH Drug
March 19, 2020
The Institute for Clinical and Economic Review (ICER) released a draft evidence report on Intercept Pharmaceuticals’ obeticholic acid for the treatment of nonalcoholic steatohepatitis (NASH).
According to a press release, a public comment period for the report will remain open until 5 p.m. EST June 24.
To read the draft report, click here.